Grace Therapeutics Announces Presentation of Abstract at SVIN Annual Meeting: Novel GTx-104 Trial Results to be Presented.
ByAinvest
Tuesday, Nov 11, 2025 8:31 am ET1min read
GRCE--
Grace Therapeutics announced an abstract for its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH has been accepted for presentation at the Society of Vascular and Interventional Neurology annual meeting. The trial compares the safety and tolerability of GTx-104 (nimodipine injection for IV infusion) to oral nimodipine in patients with aneurysmal subarachnoid hemorrhage. The presentation will be given by Thomas P Bleck, MD, on November 21, 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet